促红细胞生成素诱导的18F-PSMA-11骨髓下沉效应
一例转移性前列腺腺癌患者在接受177Lu-PSMA-617治疗后PSA升高,行18F-PSMA-11 PET/CT再分期,图像显示骨髓弥漫均匀摄取而CT未见弥漫浸润,已知淋巴结和肝转移摄取显著减少或缺失。患者24小时前曾接受重组人促红细胞生成素100 µg治疗肾性贫血,作者认为该药可刺激骨髓PSMA阳性新生血管形成,竞争放射性示踪剂,导致骨髓下沉效应并降低已知转移灶可见度。
要点
- 促红细胞生成素可在给药后24小时引起骨髓弥漫性PSMA摄取增高。
- 该效应可降低已知前列腺癌转移灶对18F-PSMA-11的摄取可见度。
- 需警惕误判为弥漫骨髓转移及后续177Lu-PSMA-617不必要的骨髓毒性。
核心结论
- 促红细胞生成素可诱导18F-PSMA-11骨髓下沉效应,导致骨髓弥漫摄取并降低已知转移灶可见度,需避免误判。
研究设计与样本
- 单例转移性前列腺腺癌患者的病例报告,患者接受177Lu-PSMA-617治疗后因PSA升高行18F-PSMA-11 PET/CT再分期。
主要发现
- MIP图像示骨髓弥漫均匀示踪剂摄取,CT示特定骨转移但无弥漫浸润,已知淋巴结和肝转移摄取显著减少或缺失。
- 同一示踪剂批次的其他患者均无类似表现,排除游离18F为可能原因。
- 患者无既往报道可致PSMA靶向PET/CT骨髓弥漫摄取的骨髓疾病。
- 患者24小时前接受重组人促红细胞生成素100 µg治疗肾性贫血。
关键数值与推荐
- Aranesp 100 µg给药后24小时成像,该剂量在骨髓达纳摩尔浓度。
- 促红细胞生成素对骨髓动员和新生血管化的效应可持续7-10天。
临床怎么用
- 解读18F-PSMA-11 PET/CT骨髓弥漫摄取时,应询问近期促红细胞生成素使用史。
- 避免将促红细胞生成素诱导的骨髓摄取误判为弥漫骨髓转移。
- 避免因此误判而给予177Lu-PSMA-617导致不必要的骨髓毒性。
局限性
- 仅为单例病例报告,因果关系基于作者推论和既往文献。
- 未提供定量摄取参数或对照统计数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A patient with metastasized prostate adenocarcinoma underwent 18F-PSMA-11 PET/CT restaging following 177Lu-PSMA-617 treatment and rising PSA-level. The maximum intensity projection image (right-side of the figure) demonstrated an intense homogenous tracer uptake throughout the bone marrow containing skeleton, whereas CT images showed specific bone metastases but no diffuse involvement, and previously known lymph node and liver metastases exhibited significantly reduced or absent uptake (see also left-side of the image, 18F-PSMA-11 MIP prior to 177Lu-PSMA-617 therapy). None of the patients that underwent imaging with the same tracer-batch demonstrated similar findings excluding free 18F as a potential cause for the imaging findings. Furthermore, the patient did not suffer from any bone marrow disorder previously reported to present with diffuse bone marrow uptake on PSMA-targeting PET/CT imaging [1, 2]. Of interest, the patient had received recombinant human erythropoietin, 100 µg of Aranesp, 24 h prior to imaging to treat his renal failure associated anemia. At this dose, Aranesp reaches a nanomolar concentration in the bone marrow resulting in stimulation of the Tissue Protective Receptor on endothelial cells leading to the creation of a massive systemic reservoir of PSMA-positive neovasculature that outcompetes PSMA-expressing prostate carcinoma lesions for radiotracer availability [3, 4]. This may explain the diffuse marrow uptake and the decreased visibility of known metastases [4]. The effect of erythropoietin on bone marrow mobilization and neovascularization can persist for 7-10 days [5]. This should be taken into consideration in order to avoid erroneous interpretation of 18F-PMSA-11 PET/CT imaging and unnecessary bone marrow toxicity of 177Lu-PSMA-617 treatment.
引用
- Maes J, Maes A, Muylle K, et al. Eryhtropoetin induced 18F-PSMA-11 bone marrow sink effect. Eur J Nucl Med Mol Imaging. 2026. PMID: 42265325. doi:10.1007/s00259-026-07957-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。